Sugi Predict

Sugi Predict / Compounds / SCHEMBL2933744

SCHEMBL2933744

SCHEMBL2933744

CCOC(=O)c1ccnc(CO)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JMJD6 Q6NYC1 4/20 0.55
▸ KDM5B Q9UGL1 3/20 0.54
▸ KDM5A P29375 1/20 0.54
▸ KDM5C P41229 1/20 0.54
▸ KDM4C Q9H3R0 1/20 0.54
▸ PIK3CA P42336 1/20 0.52
▸ CA12 O43570 3/20 0.50
▸ CA1 P00915 3/20 0.50
▸ CA2 P00918 3/20 0.50
▸ CA7 P43166 3/20 0.50
▸ CA9 Q16790 3/20 0.50
▸ CA14 Q9ULX7 3/20 0.50
▸ CDC7 O00311 1/20 0.46
▸ DBF4 Q9UBU7 1/20 0.46
▸ ESR1 P03372 1/20 0.46
▸ ESR2 Q92731 1/20 0.46
▸ CYP4F2 P78329 1/20 0.46
▸ CYP4A11 Q02928 1/20 0.46
▸ HSD17B2 P37059 1/20 0.45
▸ LMNA P02545 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30607269 1.00 JMJD6 (0.55) JMJD6KDM5BKDM5AKDM5CKDM4C
SCHEMBL3727609 0.89 JMJD6 (0.56) JMJD6KDM5BKDM5AKDM5CKDM4C
SCHEMBL7376424 0.86 JMJD6 (0.53) JMJD6KDM5BKDM5AKDM5CKDM4C
SCHEMBL3872835 0.86 JMJD6 (0.53) JMJD6KDM5BKDM5AKDM5CKDM4C
SCHEMBL14825305 0.86 JMJD6 (0.53) JMJD6KDM5BKDM5AKDM5CKDM4C
Hydrochloric Acid SCHEMBL30607263 0.84 JMJD6 (0.52) JMJD6KDM5BKDM5AKDM5CKDM4C
Hydrochloric Acid SCHEMBL17113065 0.84 JMJD6 (0.52) JMJD6KDM5BKDM5AKDM5CKDM4C
SCHEMBL27045839 0.84 JMJD6 (0.52) JMJD6KDM5BKDM5AKDM5CKDM4C
SCHEMBL22912513 0.84 JMJD6 (0.52) JMJD6KDM5BKDM5AKDM5CKDM4C
SCHEMBL17143954 0.84 CYP4F2 (0.53) JMJD6KDM5BKDM5AKDM5CKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190000832-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF Selder Pharma Inc. (US) 2019-01-03 — — US disclosed
US-20190000832-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF Selder Pharma Inc. (US) 2019-01-03 — — US disclosed
US-10016410-B2 Tetrahydroisoquinolin-1-one derivative or salt thereof SELDAR PHARMA INC. (US) 2018-07-10 — — US disclosed
US-10016410-B2 Tetrahydroisoquinolin-1-one derivative or salt thereof SELDAR PHARMA INC. (US) 2018-07-10 — — US disclosed
US-10016410-B2 Tetrahydroisoquinolin-1-one derivative or salt thereof SELDAR PHARMA INC. (US) 2018-07-10 — — US disclosed
US-20170189390-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF SELDAR PHARMA INC. (US) 2017-07-06 — — US disclosed
US-20170189390-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF SELDAR PHARMA INC. (US) 2017-07-06 — — US disclosed
US-20170189390-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF SELDAR PHARMA INC. (US) 2017-07-06 — — US disclosed
US-9526719-B2 Tetrahydroisoquinolin-1-one derivative or salt thereof SELDAR PHARMA INC. (US) 2016-12-27 — — US disclosed
US-9526719-B2 Tetrahydroisoquinolin-1-one derivative or salt thereof SELDAR PHARMA INC. (US) 2016-12-27 — — US disclosed
WO-2011142716-A1 NOVEL HEMIFUMARATE SALT OF ISOINDOLE COMPOUND ACTING AS BACE INHIBITOR ASTRAZENECA AB (SE) 2011-11-17 — — WO disclosed
US-20110281894-A1 HEMIFUMARATE SALT ASTRAZENECA AB (SE) 2011-11-17 — — US disclosed
US-20110281894-A1 HEMIFUMARATE SALT ASTRAZENECA AB (SE) 2011-11-17 — — US disclosed
US-20100227866-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-09 — — US disclosed
US-20100227866-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-09 — — US disclosed
US-20100227866-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2010-09-09 — — US disclosed
EP-2149561-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2010-02-03 — — EP disclosed
EP-2149561-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2010-02-03 — — EP disclosed
US-5234946-A Anticholesterol, antilipemic BANYU PHARMACEUTICAL CO., LTD. (JP) 1993-08-10 — — US disclosed
EP-0395768-A1 SUBSTITUTED ALLYLAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE BANYU PHARMACEUTICAL CO., LTD. (JP) 1990-11-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281894-A1 HEMIFUMARATE SALT PSEN1, PSEN2, SNCA JMJD6 3002/4885KDM5B 3762/4885KDM5A 3776/4885
US-20170189390-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF BRS3, BDKRB2, NTSR2 JMJD6 3403/4885KDM5B 3674/4885KDM5A 4326/4885
US-10016410-B2 Tetrahydroisoquinolin-1-one derivative or salt thereof BRS3, BDKRB2, NTSR2 JMJD6 3403/4885KDM5B 3674/4885KDM5A 4326/4885
US-20100227866-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF BRS3, BDKRB2, NTSR2 JMJD6 3510/4885KDM5B 3674/4885KDM5A 4398/4885
US-20190000832-A1 TETRAHYDROISOQUINOLIN-1-ONE DERIVATIVE OR SALT THEREOF BRS3, BDKRB2, NTSR2 JMJD6 3403/4885KDM5B 3674/4885KDM5A 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.